Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study [0.03%]
一项Ⅰ期人体试验：在晚期实体瘤患者中评估新型ALK5抑制剂vactosertib的药代动力学特征
Su Young Jung,Sunjin Hwang,Jeffery M Clarke et al.
Su Young Jung et al.
Purposes Vactosertib is a new investigational inhibitor of activin receptor-like kinase 5. The objective of this study was to characterize vactosertib pharmacokinetics that are to be applied for subsequent clinical studies. Methods Vactoser...
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma [0.03%]
PF-04136309（一种口服CC趋化因子受体2拮抗剂）联合白蛋白结合型紫杉醇/吉西他滨一线治疗胰腺导管腺癌的Ⅰb期临床研究
Marcus Noel,Eileen M O&#x;Reilly,Brian M Wolpin et al.
Marcus Noel et al.
Background In pancreatic ductal adenocarcinoma (PDAC), the chemokine (C-C motif) ligand 2 (CCL2)/chemokine (C-C motif) receptor 2 (CCR2) axis plays a key role in immunosuppressive properties of the tumor microenvironment, patient prognosis,...
Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls [0.03%]
廉价的肮脏勾当：利用羟基多氯联苯增强前列腺癌细胞对阿比特龙的敏感性
Gabriel Daragan,Jenny Hoffmann,Theresa Vasko et al.
Gabriel Daragan et al.
Effective targeting of androgen biosynthesis by the 17α-hydroxylase/17,20-lyase inhibitor abiraterone prolongs survival in a variety of prostate cancer patients. However, resistance to abiraterone treatment occurs frequently and the develo...
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study [0.03%]
新辅助或辅助化疗后用于三阴性乳腺癌的TS-1添加治疗：一项可行性研究
Kenichi Inoue,Shigenori E Nagai,Tsuyoshi Saito et al.
Kenichi Inoue et al.
Purpose We examined the feasibility, efficacy, and safety of TS-1 add-on therapy (TAT) in Japanese patients with triple-negative breast caner (TNBC). Methods TAT (TS-1, 80 mg/m2/day, BID, PO), consisting of the 21-day cycles of 14-day conse...
Multicenter Study
Investigational new drugs. 2020 Feb;38(1):140-147. DOI:10.1007/s10637-019-00829-w 2020
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [0.03%]
自噬抑制可增强ruxolitinib诱导的JAK2V617F细胞凋亡作用
João Agostinho Machado-Neto,Juan Luiz Coelho-Silva,Fábio Pires de Souza Santos et al.
João Agostinho Machado-Neto et al.
JAK2V617F can mimic growth factor signaling, leading to PI3K/AKT/mTOR activation and inhibition of autophagy. We hypothesized that selective inhibition of JAK1/2 by ruxolitinib could induce autophagy and limit drug efficacy in myeloprolifer...
Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia [0.03%]
基于TLR7化合物的设计、合成及化疗引起的脱发生物活性研究
Jincheng Yang,Kun Chen,Bin Wang et al.
Jincheng Yang et al.
Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics. Imiquimod application at mid and late telogen activated the hair follicle stem cells leading to premature hair cycle entry. Based on quinoline structure, ...
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer [0.03%]
长链非编码RNA-DANCR通过调控miR-135a/NLRP37轴促进胰腺癌的增殖和侵袭
Yong Tang,Guojun Cao,Gang Zhao et al.
Yong Tang et al.
Background It is well-known that long-chain non-coding RNA (LncRNA) plays an important role in the development of tumor. DANCR, which is one crucial part of the lncRNA family, has been shown to be involved in the invasion of various tumors....
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting [0.03%]
靶向B7-H3的T细胞对血液系统恶性肿瘤的细胞毒性作用
Xin Sun,Yang Yu,Li Ma et al.
Xin Sun et al.
T cells are important effectors in anti-tumor immunity, and aberrant expression of B7 family members may contribute to tumor evasion. In this study, we analyzed expression of costimulatory molecules on human hematologic tumor cells and expl...
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction [0.03%]
一种新的BET抑制剂通过抑制细胞增殖而不是诱导细胞凋亡来抑制肿瘤生长
Mohammadali Soleimani Damaneh,Jian-Ping Hu,Xia-Juan Huan et al.
Mohammadali Soleimani Damaneh et al.
The bromodomain and extra-terminal domain (BET) family of proteins, especially bromodomain-containing protein 4 (BRD4), has emerged as exciting anti-tumor targets due to their important roles in epigenetic regulation. Therefore, the discove...
Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma [0.03%]
Taurolidine的双重功能可有效抑制小儿神经母细胞瘤的生长与发展
Lucy Swift,Chunfen Zhang,Olga Kovalchuk et al.
Lucy Swift et al.
High-risk, relapsed and refractory neuroblastoma are associated with poor 5-years survival rates, demonstrating the need for investigational therapeutic agents to treat this disease. Taurolidine is derived from the aminosulfoacid taurine an...